>> This adds validity to the claim that CTL-4 blockade is an effective immunomodulatory strategy. <<
When some companies are developing drugs which up-regulate CTLA-4 (MEDX) and other companies are developing drugs which down-regulate CTLA-4 (BMY), it’s a good sign that CTLA-4 is a promising target for pharmaceutical intervention.